Thromboprophylaxis for Total Knee Arthroplasty^[*]

Abstract

The authors report an update of the main methods for preventing deep vein thrombosis after total knee replacement, which are divided into mechanical and pharmacological methods. The current principal used drugs, their dosages, and the comparative risks and benefits are also reported.

Keywords

total knee replacement - complications - venous thrombosis - prevention

^* Work developed at the Departament of Ortopedics, Faculty of Medical Sciences and Health, Pontifícia Universidade Católica de São Paulo (PUC-SP), Sorocaba, SP, Brazil.

• Referências

• 1 Song K, Xu Z, Rong Z, Yang X, Yao Y, Shen Y. , et al. The incidence of venous thromboembolism following total knee arthroplasty: a prospective study by using computed tomographic pulmonary angiography in combination with bilateral lower limb venography. Blood Coagul Fibrinolysis 2016; 27 (03) 266-9
• 2 Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P. , et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 1999; 81 (04) 654-9
• 3 Lachiewicz PF, Kelley SS, Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomised study. J Bone Joint Surg Br 2004; 86 (08) 1137-41
• 4 He ML, Xiao ZM, Lei M, Li TS, Wu H, Liao J. Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty. Cochrane Database Syst Rev 2014; (07) CD008207
• 5 Barrack RL. Current guidelines for total joint VTE prophylaxis: dawn of a new day. J Bone Joint Surg Br 2012; 94 (11, Suppl A): 3-7
• 6 Parvizi J, Jacovides CL, Bican O, Purtill JJ, Sharkey PF, Hozack WJ. , et al. Is deep vein thrombosis a good proxy for pulmonary embolus?. J Arthroplasty 2010; 25 (6, Suppl) 138-44
• 7 Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG. , et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am 2012; 94 (08) 746-7
• 8 Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006; 452 (452) 175-80
• 9 Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW. Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. J Arthroplasty 2008; 23 (06) (Suppl. 01) 20-4
• 10 Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?. J Arthroplasty 2010; 25 (07) 1053-60
• 11 Parvizi J, Huang R, Restrepo C, Chen AF, Austin MS, Hozack WJ. , et al. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am 2017; 99 (02) 91-8
• 12 Liu F, Chu X, Huang J, Tian K, Hua J, Tong P. Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention. Arch Orthop Trauma Surg 2014; 134 (05) 679-83
• 13 Arsoy D, Giori N, Woolson S. Mechanical Compression Reduces Readmissions and Wound Complications from Low Molecular Weight Heparin after Total Hip or Knee Arthroplasty. San Diego: AAOS Annual Meeting; 2017
• 14 Bauer KA, Eriksson BI, Lassen MR, Turpie AG. ; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345 (18) 1305-10
• 15 Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ. , et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-86
• 16 Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA. , et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag 2014; 10 (10) 157-67
• 17 Bloch BV, Patel V, Best AJ. Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. Bone Joint J 2014; 96-B (01) 122-6
• 18 Yoshida RA, Yoshida WB, Rollo HA. Novos anticoagulantes orais para a profilaxia e tratamento do tromboembolismo venoso em cirurgias ortopédicas de grande porte. J Vasc Bras 2011; 10 (02) 145-53
• 19 Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT. , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012; 94 (02) 257-64
• 20 Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344: e3675
• 21 Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgrad Med 2013; 125 (04) 141-53
• 22 Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T. , et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 2014; 134 (06) 1198-204
• 23 Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH. , et al; EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101 (01) 68-76
• 24 Parvizi J, Huang R, Raphael IJ, Maltenfort MG, Arnold WV, Rothman RH. Timing of Symptomatic Pulmonary Embolism with Warfarin Following Arthroplasty. J Arthroplasty 2015; 30 (06) 1050-3
• 25 Miyagi J, Funabashi N, Suzuki M, Asano M, Kuriyama T, Komuro I. , et al. Predictive indicators of deep venous thrombosis and pulmonary arterial thromboembolism in 54 subjects after total knee arthroplasty using multislice computed tomography in logistic regression models. Int J Cardiol 2007; 119 (01) 90-4
• 26 Bohl DD, Maltenfort MG, Huang R, Parvizi J, Lieberman JR, Della Valle CJ. Development and Validation of a Risk Stratification System for Pulmonary Embolism After Elective Primary Total Joint Arthroplasty. J Arthroplasty 2016; 31 (9, Suppl) 187-91
• 27 Plante S, Belzile EL, Fréchette D, Lefebvre J. Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty. Can J Surg 2017; 60 (01) 30-6
• 28 Newman JM, Abola MV, Macpherson A, Klika AK, Barsoum WK, Higuera CA. ABO Blood Group Is a Predictor for the Development of Venous Thromboembolism After Total Joint Arthroplasty. J Arthroplasty 2017; 32 (9S): S254-8